Last quarter (Q4 2023), Kazia Therapeutics's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Kazia Therapeutics's net income was AU$―. See Kazia Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 23	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	-	-	-	AU$ 15.18M	AU$ 0.00	AU$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	AU$ 15.18M	-	-
Operating Expense	-	AU$ 24.15M	AU$ 24.76M	AU$ 21.56M	AU$ 12.19M	AU$ 8.82M
Operating Income	-	AU$ -24.15M	AU$ -24.76M	AU$ -21.56M	AU$ -12.19M	AU$ -8.82M
Net Non Operating Interest Income Expense	-	AU$ 22.56K	AU$ 2.00K	AU$ 15.22M	AU$ 66.00K	AU$ 100.00K
Other Income Expense	-	AU$ -3.39M	AU$ 24.89M	AU$ 10.99M	AU$ -637.00K	AU$ -1.85M
Pretax Income	-	AU$ -20.74M	AU$ -25.02M	AU$ -8.91M	AU$ -12.77M	AU$ -10.57M
Tax Provision	-	AU$ -271.09K	AU$ -368.00K	AU$ -484.00K	AU$ -298.00K	AU$ -298.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	AU$ -20.47M	AU$ -73.90M	AU$ -25.26M	AU$ -12.47M	AU$ -10.27M
Basic EPS	-	AU$ -0.11	AU$ -0.19	AU$ -0.07	-	-
Diluted EPS	-	AU$ -0.11	AU$ -0.19	AU$ -0.07	-	-
Basic Average Shares	-	AU$ 184.28M	AU$ 388.94M	AU$ 360.91M	-	-
Diluted Average Shares	-	AU$ 184.28M	AU$ 388.94M	AU$ 360.91M	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	AU$ 24.15M	AU$ 24.76M	AU$ 21.56M	AU$ 12.19M	AU$ 8.82M
Net Income From Continuing And Discontinued Operation	-	AU$ -20.47M	AU$ -73.90M	AU$ -25.26M	AU$ -12.47M	AU$ -10.27M
Normalized Income	-	-	-	-	AU$ -11.84M	AU$ -8.45M
Interest Expense	-	-	-	-	-	-
EBIT	-	-	AU$ -25.02M	AU$ -8.91M	AU$ -12.19M	AU$ -8.82M
EBITDA	-	-	AU$ -23.06M	AU$ -7.64M	AU$ -11.11M	AU$ -7.74M

Currency in AUD

Kazia Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing